Clinical trial recruitment and retention remain challenges in the quest to bring innovative therapies to all patients in need. In oncology, therapies continue to evolve, yet researchers are frequently faced with low trial participation, particularly among minority groups. The Oncology Pharmacist (TOP) is dedicated to providing comprehensive information aimed at eliminating health disparities and improving access to therapies for people from all populations, including racial and ethnic minorities; people with limited access to healthcare due to lack of financial resources; and people living in rural communities.
This new feature in TOP aims to provide ongoing lists of US-based phase 2 or 3 clinical trials that are actively recruiting. This issue is focused on sarcoma, the July cancer awareness month. Pharmacists may use this listing in discussions with their patients to encourage enrollment. As the National Comprehensive Cancer Network has stated, “The best management of any cancer patient is in a clinical trial.”
These clinical trial listings can be found at www.ClinicalTrials.gov.
Actively Seeking Minority Patients
- Metastatic Leiomyosarcoma Biomarker Protocol
- ClinicalTrials.gov identifier: NCT05653388
- Sponsor: University of Michigan Rogel Cancer Center
- Collaborator: National Cancer Institute
- Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
- ClinicalTrials.gov Identifier: NCT05857969
- Sponsor: Florida International University
- Collaborators
- Nicklaus Children's Hospital f/k/a Miami Children's Hospital
- First Ascent Biomedical, Inc.
- National Institute on Minority Health and Health Disparities
Actively Seeking All Patients
- Feasibility Trial of Preoperative 5-Day Hypofractionated Radiotherapy for Primary Soft Tissue Sarcoma
- ClinicalTrials.gov identifier: NCT05776667
- Sponsor: Medical University of South Carolina
- Dose Reduction of Postoperative Radiation for Soft Tissue Sarcoma of the Arms and Legs
- ClinicalTrials.gov Identifier: NCT04288375
- Sponsor: Memorial Sloan Kettering Cancer Center
- Collaborator: National Institutes of Health
- Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma (TNT)
- ClinicalTrials.gov identifier: NCT03886311
- Sponsor: Sarcoma Oncology Research Center, LLC
- 5-Day Preoperative Radiation for Soft Tissue Sarcoma
- ClinicalTrials.gov identifier: NCT06087861
- Sponsor: Stanford University
- GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma
- ClinicalTrials.gov identifier: NCT04535713
- Sponsor: Sarcoma Oncology Research Center, LLC
- A Study of sEphB4-HSA in Kaposi Sarcoma
- ClinicalTrials.gov identifier: NCT03993106
- Sponsor: Vasgene Therapeutics, Inc
- Habitat Escalated Adaptive Therapy (HEAT), With Neoadjuvant Radiation for Soft Tissue Sarcoma
- ClinicalTrials.gov identifier: NCT05301283
- Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- Collaborator: Viewray Inc.
- A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma
- ClinicalTrials.gov identifier: NCT05755113
- Sponsor: QBiotics Group Limited
- Hypofractionated vs Conventional Fractionated RT in Soft Tissue Sarcomas
- ClinicalTrials.gov identifier: NCT05109494
- Sponsor: University of Wisconsin, Madison
- Pomalidomide Treatment in Patients With Kaposi Sarcoma
- ClinicalTrials.gov identifier: NCT04577755
- Sponsor: National Cancer Institute
- Hypofractionated Radiotherapy Followed by Surgical Resection in the Treatment of Soft Tissue Sarcomas
- ClinicalTrials.gov identifier: NCT04506008
- Sponsor: Vanderbilt-Ingram Cancer Center
- sEphB4-HSA in Treating Patients With Kaposi Sarcoma
- ClinicalTrials.gov IIdentifier: NCT02799485
- Sponsor: AIDS Malignancy Consortium
- Collaborators
- National Cancer Institute
- Vasgene Therapeutics, Inc
- The Emmes Company, LLC
- University of Arkansas
- Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma
- ClinicalTrials.gov identifier: NCT04204941
- Sponsor: Epizyme, Inc.
- Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas
- ClinicalTrials.gov identifier: NCT04028063
- Sponsor: University of Colorado, Denver
- Collaborator: Agenus Inc.
- Trial of Ixazomib for Kaposi Sarcoma
- ClinicalTrials.gov identifier: NCT04305691
- Sponsor: AIDS Malignancy Consortium
- Collaborator: National Cancer Institute
- Testing Atezolizumab With or Without Selinexor in Patients >= 18 Years Old With Alveolar Soft Part Sarcoma, the Axiom Study
- ClinicalTrials.gov identifier: NCT05333458
- Sponsor: National Cancer Institute
- Evaluating the Impact of Limited Compared With Intense Post-Operative Surveillance on Patient-Reported Outcomes in Patients With Stage II-III Soft Tissue Sarcoma of the Trunk and Extremities
- ClinicalTrials.gov identifier: NCT04751409
- Sponsor: M.D. Anderson Cancer Center
- Iscador® P (Mistletoe) Immunotherapy for Recurrent Osteogenic Sarcoma
- ClinicalTrials.gov identifier: NCT05726383
- Sponsor: Hackensack Meridian Health
- Collaborators
- M.D. Anderson Cancer Center
- Iscador AG, Arlesheim, Switzerland
- Tackle Kids Cancer
- Susan Zabransky Hughes Foundation
- CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma
- ClinicalTrials.gov identifier: NCT05440786
- Sponsor: Eli Lilly and Company
- Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration
- ClinicalTrials.gov identifier: NCT04040205
- Sponsor: Medical College of Wisconsin